MA33569B1 - Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie - Google Patents

Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie

Info

Publication number
MA33569B1
MA33569B1 MA34669A MA34669A MA33569B1 MA 33569 B1 MA33569 B1 MA 33569B1 MA 34669 A MA34669 A MA 34669A MA 34669 A MA34669 A MA 34669A MA 33569 B1 MA33569 B1 MA 33569B1
Authority
MA
Morocco
Prior art keywords
prevention
treatment
sigma
ligament
chemotherapy pain
Prior art date
Application number
MA34669A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
José Manuel Baeyens-Cabrera
Helmut Heinrich Buschmann
Hernández José Miguel Vela
Daniel Zamanillo-Castanedo
Francisco-Rafael Nieto-López
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA33569B1 publication Critical patent/MA33569B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA34669A 2009-08-14 2012-03-08 Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie MA33569B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382144A EP2292236A1 (en) 2009-08-14 2009-08-14 Sigma ligands for the prevention or treatment of pain induced by chemotherapy
PCT/EP2010/061720 WO2011018487A1 (en) 2009-08-14 2010-08-12 Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Publications (1)

Publication Number Publication Date
MA33569B1 true MA33569B1 (fr) 2012-09-01

Family

ID=41531868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34669A MA33569B1 (fr) 2009-08-14 2012-03-08 Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie

Country Status (34)

Country Link
US (3) US20120141606A1 (enExample)
EP (2) EP2292236A1 (enExample)
JP (1) JP5922575B2 (enExample)
KR (3) KR101605151B1 (enExample)
CN (1) CN102497864B (enExample)
AR (1) AR077876A1 (enExample)
AU (2) AU2010283761B2 (enExample)
BR (1) BR112012003053A2 (enExample)
CA (1) CA2770441C (enExample)
CO (1) CO6511240A2 (enExample)
CY (1) CY1116697T1 (enExample)
DK (1) DK2464356T3 (enExample)
EC (1) ECSP12011658A (enExample)
ES (1) ES2543645T3 (enExample)
HR (1) HRP20150788T1 (enExample)
HU (1) HUE025642T2 (enExample)
IL (1) IL217911A0 (enExample)
IN (1) IN2012DN02149A (enExample)
MA (1) MA33569B1 (enExample)
MX (1) MX2012001877A (enExample)
MY (1) MY157334A (enExample)
NZ (1) NZ598213A (enExample)
PH (1) PH12012500286A1 (enExample)
PL (1) PL2464356T3 (enExample)
PT (1) PT2464356E (enExample)
RU (1) RU2543382C2 (enExample)
SG (1) SG178338A1 (enExample)
SI (1) SI2464356T1 (enExample)
SM (1) SMT201500189T1 (enExample)
TN (1) TN2012000048A1 (enExample)
TW (1) TWI529168B (enExample)
UA (1) UA108859C2 (enExample)
WO (1) WO2011018487A1 (enExample)
ZA (1) ZA201200843B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
MX2016002892A (es) * 2013-09-12 2016-06-10 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine.
SG11201604478UA (en) 2013-12-17 2016-07-28 Esteve Labor Dr Gabapentinoids and sigma receptor ligands combinations
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
EP3463339B1 (en) 2016-06-06 2023-12-06 Esteve Pharmaceuticals, S.A. Use of sigma receptor ligands in cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2024105225A1 (en) * 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
FR2301250A1 (fr) * 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
AU2005276590B2 (en) 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
JP2009528315A (ja) * 2006-03-01 2009-08-06 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ シグマ受容体阻害剤としてのピラゾール誘導体
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
EP2464356A1 (en) 2012-06-20
SMT201500189T1 (it) 2015-09-07
HK1171945A1 (en) 2013-04-12
HUE025642T2 (en) 2016-04-28
DK2464356T3 (en) 2015-07-13
KR20150140419A (ko) 2015-12-15
SG178338A1 (en) 2012-03-29
IN2012DN02149A (enExample) 2015-08-07
IL217911A0 (en) 2012-03-29
CA2770441A1 (en) 2011-02-17
RU2012109554A (ru) 2013-09-20
MY157334A (en) 2016-05-31
SI2464356T1 (sl) 2015-08-31
AU2010283761A1 (en) 2012-03-08
WO2011018487A1 (en) 2011-02-17
CN102497864B (zh) 2015-07-22
US20160199380A1 (en) 2016-07-14
KR20120055692A (ko) 2012-05-31
BR112012003053A2 (pt) 2016-08-02
CO6511240A2 (es) 2012-08-31
PH12012500286A1 (en) 2015-06-26
CN102497864A (zh) 2012-06-13
NZ598213A (en) 2014-05-30
UA108859C2 (uk) 2015-06-25
HRP20150788T1 (hr) 2015-08-28
EP2292236A1 (en) 2011-03-09
JP5922575B2 (ja) 2016-05-24
AU2016228207B2 (en) 2017-09-07
AU2016228207A1 (en) 2016-11-03
TN2012000048A1 (en) 2013-09-19
ECSP12011658A (es) 2012-03-30
KR101605151B1 (ko) 2016-03-21
AR077876A1 (es) 2011-09-28
US20120141606A1 (en) 2012-06-07
CA2770441C (en) 2017-12-12
ZA201200843B (en) 2012-10-31
AU2010283761B2 (en) 2016-10-13
EP2464356B1 (en) 2015-05-06
CY1116697T1 (el) 2017-03-15
US20160220575A1 (en) 2016-08-04
TW201121959A (en) 2011-07-01
JP2013501754A (ja) 2013-01-17
RU2543382C2 (ru) 2015-02-27
KR20170125951A (ko) 2017-11-15
MX2012001877A (es) 2012-04-11
ES2543645T3 (es) 2015-08-20
PT2464356E (pt) 2015-08-31
PL2464356T3 (pl) 2015-10-30
TWI529168B (zh) 2016-04-11

Similar Documents

Publication Publication Date Title
MA33569B1 (fr) Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
MA32171B1 (fr) Compose heterocyclique
MA34506B1 (fr) Utilisation de ligands sigma dans une hyperalgie induite par des opioides
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
MA32965B1 (fr) Derives de sulfonamides
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MA34308B1 (fr) Triazolopyridines substituées
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MA39147B1 (fr) Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
DE602004011494D1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
DE602007007934D1 (en) Imidazoazephinonverbindungen
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
MA37438A1 (fr) Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
UA94053C2 (ru) Замещенные производные 3-сульфонилиндазола в качестве лигандов гидрокситриптамина-6